We are proud to announce that Biocytogen will be attending the 1st Annual European Neuroscience Innovation Forum in Zurich, Switzerland. After years of successful conferences in the USA, the Neuroscience Innovation Forum is finally being brought to Europe to convene corporate and financial investors, pharma executives, and advisors in addressing the latest global developments in CNS. We look forward to meeting you there!
What is the 1st Annual European Neuroscience Innovation Forum?
The 1st Annual European Neuroscience Innovation Forum will be serving as an insightful forum to 250+ delegates across the neuroscience ecosystem. It will feature a full day of panels, keynote speakers, and presentations covering next-gen therapies and tech innovation in Europe. There will be plenty of opportunities to connect and engage with stakeholders, both in-person during the networking reception and virtually through the online meeting system.
Event Overview
Date: March 3rd, 2026
Venue: Hilton Zurich Airport, Hohenbühlstrasse 10, 8152 Opfikon, Switzerland
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s shape the future of neuroscience together, we look forward to seeing you in Switzerland!
